Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow, Margaret K. Callahan, Jedd D. Wolchok · Journal of Clinical Oncology · 2015
Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced melanoma, and additional regulatory approvals are expected across the oncologic spectrum for a variety of other agents that target these pathways. Treatment with both CTLA-4 and PD-1/PD-L1 blockade is associated with a unique pattern of adverse events called immune-related adverse events, and occasionally, unusual kinetics of tumor response are seen. Combination approaches involving CTLA-4 and PD-1/PD-L1 blockade are being investigated to determine whether they enhance the efficacy of either approach alone. Principles learned during the development of CTLA-4 and PD-1/PD-L1 approaches will likely be used as new immunologic checkpoint blocking antibodies begin clinical investigation.
Cited by 2,709 works. doi:10.1200/jco.2014.59.4358
Authors
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
- Nivolumab plus Ipilimumab in Advanced Melanoma